FRI0270 ONE-YEAR EFFECTIVENESS, RETENTION RATE AND SAFETY OF SECUKINUMAB IN ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS: A REAL-LIFE MULTICENTRE STUDY. (2nd June 2020)

• Record Type: Journal Article
• Authors: Chimenti, M. S.; Fonti, G. L.; Conigliaro, P.; Sunzini, F.; Scrivo, R.; Navarini, L.; Triggianese, P.; Peluso, G.; Scolieri, P.; Caccavale, R.; Picchianti-Diamanti, A.; De Martino, E.; Salemi, S.; Birra, D.; Altobelli, A.; Paroli, M.; Bruzzese, V.; Laganà, B.; Gremese, E.; Conti, F.; Afeltra, A.; Perricone, R.
• Is Part Of: Annals of the rheumatic diseases. Volume 79(2020)Supplement 1
• Page Start: 720
• Page End: 720
• Publication Date: 2020-06-02
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2020-eular.3777
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Secukinumab (SEC) is the first interleukin-17A inhibitor showing efficacy in both ankylosing spondylitis (AS) and psoriatic arthritis (PsA) in randomised trials, but real-life data are lacking. Objectives: In this prospective observational study, we evaluated the effectiveness and safety of SEC in patients with AS and PsA in a real-life setting. Methods: From September 2018 to September 2019, data were collected from 168 consecutive outpatients at baseline (T0) and at 6 (T6) and 12 months (T12) after starting SEC (39 AS, 23%; 129 PsA, 77%). Results: Significant improvement was seen at T6 and T12 for all clinical variables, including TJC, SJC, ESR, CRP, DAPSA, ASDAS-CRP, and BASDAI, as well as in patient-reported outcomes such as VAS-pain. By multivariable regression analysis, in AS patients high BASDAI at T0 correlated with diagnostic delay (R 2 =0.4; p=0.009) and peripheral joint involvement (R 2 =0.4; p=0.04). During follow-up, reduction of BASDAI positively correlated with high ESR (R 2 =0.65; p=0.04). ASDAS-CRP at T0 positively correlated with high ESR (R 2 =0.34; p=0.004). Reduction of ASDAS-CRP from T0 to T6 correlated with current smoking status (R 2 =0.42; p=0.0005). In PsA patients, reduction of DAPSA score from T0 to T12 negatively correlated with the presence of metabolic syndrome (R 2 =0.41; p= 0.0025). Retention rate showed good drug survival and an influence of female sex (Figure 1 ) in the survival curve in only AS patients, but no differences based on BMI, gender and lines of treatment were observed (Figure 2 ). SEC was well tolerated: Eleven patients discontinued treatment for non-severe adverse events. Conclusion: We demonstrated the effectiveness and safety of SEC in patients with AS and PsA in a real-life setting for the first time. No gender differences were observed; however, less clinical improvement was seen in smokers and in patients with metabolic syndrome References: No references. Disclosure of Interests: Maria Sole Chimenti: None declared, giulia lavinia fonti: None declared, Paola Conigliaro: None declared, flavia sunzini: None declared, Rossana Scrivo: None declared, luca navarini: None declared, paola triggianese: None declared, giusy peluso: None declared, Palma Scolieri: None declared, rosalba caccavale: None declared, Andrea Picchianti-Diamanti: None declared, erica de martino: None declared, simonetta salemi: None declared, domenico birra: None declared, Alessio Altobelli: None declared, marino paroli: None declared, Vincenzo Bruzzese: None declared, Bruno Laganà: None declared, Elisa Gremese Speakers bureau: Abbvie, BMS, Celgene, Jannsen, Lilly, MSD, Novartis, Pfizer, Sandoz, UCB, fabrizio conti Speakers bureau: BMS, Lilly, Abbvie, Pfizer, Sanofi, Antonella Afeltra: None declared, Roberto Perricone: None declared